Navigation Links
Neurocrine Biosciences Reports Fourth Quarter and Year-End 2008 Results
Date:2/3/2009

icant differences were observed in the key efficacy endpoints between 876008 and placebo.

GSK has advanced a novel lead CRF1 receptor antagonist compound, 561679, into a Phase II trial in patients with major depressive disorder. Enrollment of approximately 150 subjects is anticipated in this 6-week randomized, double-blind, placebo-controlled trial.

In addition to the two compounds listed above, GSK has also successfully completed a Phase I single dose-escalating clinical trial with a third CRF1 compound, 586529, for the treatment of anxiety and depression.

Urocortin 2 for Congestive Heart Failure (CHF) Completes Preclinical Evaluations

In December 2008 the Company completed two preclinical studies for urocortin 2 with favorable outcomes. The two GLP toxicology and safety assessment studies, over 14 days of continuous infusion, were completed in distinct species models, and confirmed the results of the two previous non-GLP studies. The favorable results of these studies should allow urocortin 2 to be infused for periods up to two weeks in duration in humans.

Vesicular Monoamine Transporter 2 Inhibitor (VMAT2)

VMAT2 is a protein concentrated in the human brain that is essential for the transmission of nerve impulses between neurons. The Company has identified a highly selective VMAT2 inhibitor that is effective in regulating the levels of dopamine release during nerve communication, while at the same time having minimal impact on the other monoamines thereby reducing the likelihood of "off target" side effects. This clinical candidate should be effective in the management of hyperkinetic movement disorders characterized by involuntary bodily movements as seen in patients suffering from Tardive Dyskinesia, and Huntington's disease. Additionally, the modulation of dopamine pathways may also be useful for patients suffering fro
'/>"/>

SOURCE Neurocrine Biosciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine news :

1. Webcast Alert: Neurocrine Announces 1Q08 Financial Results
2. Neurocrine Announces Closing of $109 Million Sale and Leaseback Agreement for its Real Estate Assets
3. Neurocrine Biosciences to Present at the CIBC World Markets 18th Annual Healthcare Conference
4. Enlight Biosciences Expands to direct up to $52 Million to Transformational Enabling Technologies
5. New Jersey-Based Biotech Start-Up Nexomics Biosciences Gets Off the Ground
6. URMC, Lighthouse Biosciences Awarded U.S. Patent for Diagnostic Technology
7. URMC, Lighthouse Biosciences awarded US patent for diagnostic technology
8. Abbott Completes Acquisition of Ibis Biosciences, a Subsidiary of Isis
9. CeloNova BioSciences Receives FDA Market Approval for Embozene(TM) Color-Advanced Microspheres Embolization Platform
10. Pressure BioSciences, Inc. Announces Restructuring, Significant Cost Reduction Initiatives, and Sharpened Focus
11. Alexander R. Giaquinto, Ph.D., Joins Regado Biosciences as Senior Vice President of Regulatory Affairs and Quality Assurance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... , ... July 28, 2015 , ... ... announced HeartPlace will be expanding their cloud presence to support their rapidly growing ... in North Texas, has been serving the Dallas/Fort Worth area for almost 50 ...
(Date:7/28/2015)... ... July 28, 2015 , ... Maryland Brain & Spine ... and, along with it, more service offerings, updated treatment techniques, and additional state-of-the art ... pain management and minimally invasive surgical treatment of brain and spine conditions. , ...
(Date:7/28/2015)... ... , ... Please join us for the 5th Annual Step for Hope 5K Run/Walk ... and Lies Road in Carol Stream. All are welcome. , Now in its 5th ... help to support individuals and families affected by a brain aneurysm. , “We look ...
(Date:7/28/2015)... ... ... Advanced Fertility Center of Texas (AFCT) has hosted the EMBCOL office ... a Reproductive Laboratory Director at AFCT, was one of the founders of EMBCOL and ... who is credited with the discovery of intra-cytoplasmic sperm injection (ICSI) , which ...
(Date:7/28/2015)... ... July 28, 2015 , ... One of ... Runner’s World Magazine, is plantar fasciitis . Zensah, the Miami-based compression brand, ... by a professional athletic trainer, the Zensah Ankle Support’s primary benefits include helping ...
Breaking Medicine News(10 mins):Health News:HeartPlace Announces Cloud Expansion with VAZATA 2Health News:HeartPlace Announces Cloud Expansion with VAZATA 3Health News:Maryland Brain & Spine Announces New Specialty, New Name 2Health News:Maryland Brain & Spine Announces New Specialty, New Name 3Health News:Maryland Brain & Spine Announces New Specialty, New Name 4Health News:5th Annual Step for Hope 5K Run/Walk Event in Carol Stream, IL to Benefit Renowned Brain Aneurysm Foundation 2Health News:Advanced Fertility Center of Texas Is Proud to Announce That Our Lab Director Has Been Re-elected as The American College of Embryology President 2Health News:Zensah Releases Compression Sleeve To Relieve Ankle Pain and Plantar Fasciitis 2
... April 21 Ground was broken on ... of Chicago today following,remarks from Children,s Memorial ... hospital leadership and public officials,(First Lady Maggie ... Rahm Emanuel, Congressman Danny Davis and Congressman ...
... quarterly net sales of $668.2 million, up 13.4% year over year and 11.5% sequentially, -- ... the same period last year, -- Record quarterly Catalysts segment income of $51.7 million resulting in ... ... First Quarter ...
... and energy; reduces food waste, GAITHERSBURG, Md., April 21 ... Sodexo will line up to get their meals in a,new ... introduced by Sodexo,as part of the company,s commitment to reduce ... of water each day,and reduces electricity and chemical use., ...
... proved more beneficial than individual grief counseling, study finds ... experience the unexpected death of a parent after a ... finding that has major implications for helping children deal ... "Often children who have lost a parent are given ...
... responds to being treated fairly the same way it responds ... treated fairly turns on the brain,s reward circuitry. ... a reward," said study co-author Matthew D. Lieberman, UCLA associate ... , "Receiving a fair offer activates the ...
... safety and,well-being of the public, the Synthetic Turf Council ... New Jersey Department of Health and,Senior Services (NJDHSS) that ... high lead levels., Dr. David Black (Ph.D. Forensic ... that there is no scientific evidence of,health risks related ...
Cached Medicine News:Health News:More Than 1,000 Children's Memorial Hospital Patients, Physicians, Elected Officials, Donors and Staff Gather to Break Ground on the Ann & Robert H. Lurie Children's Hospital of Chicago 2Health News:More Than 1,000 Children's Memorial Hospital Patients, Physicians, Elected Officials, Donors and Staff Gather to Break Ground on the Ann & Robert H. Lurie Children's Hospital of Chicago 3Health News:Albemarle Reports Record Quarterly Net Sales and Operating Results 2Health News:Albemarle Reports Record Quarterly Net Sales and Operating Results 3Health News:Albemarle Reports Record Quarterly Net Sales and Operating Results 4Health News:Albemarle Reports Record Quarterly Net Sales and Operating Results 5Health News:Albemarle Reports Record Quarterly Net Sales and Operating Results 6Health News:Albemarle Reports Record Quarterly Net Sales and Operating Results 7Health News:Albemarle Reports Record Quarterly Net Sales and Operating Results 8Health News:Albemarle Reports Record Quarterly Net Sales and Operating Results 9Health News:Albemarle Reports Record Quarterly Net Sales and Operating Results 10Health News:Sodexo Challenges Diners on College Campuses to Go Trayless and Go Green 2Health News:Treating PTSD Helps Kids Deal With Loss 2Health News:Brain reacts to fairness as it does to money and chocolate 2Health News:Experts Agree There is No Scientific Evidence of Health Risks in New Jersey Synthetic Turf Fields 2Health News:Experts Agree There is No Scientific Evidence of Health Risks in New Jersey Synthetic Turf Fields 3
(Date:7/27/2015)... CTI BioPharma Corp. (NASDAQ and MTA: CTIC) announced today ... financial results on Thursday, August 6, 2015, after the ... members of the management team will host a webcast ... general corporate update at 4:30 p.m. EDT (1:30 p.m. ... follows: Thursday, August 6 1:30 p.m. PDT/4:30 ...
(Date:7/27/2015)... PARIS , July 28, 2015   Regeneron ... into a new global collaboration to discover, develop and ... of immuno-oncology. As part of the agreement, the two ... 1 (PD-1) inhibitor currently in Phase 1 testing and ... therapeutic candidates based on ongoing, innovative preclinical programs. ...
(Date:7/27/2015)... WESTLAKE VILLAGE, Calif. , July 27, ... and KYTHERA Biopharmaceuticals, Inc. (NASDAQ: KYTH ) today ... granted early termination of the waiting period under the ... respect to Allergan,s pending acquisition of KYTHERA.  ... July 6, 2015, each of Allergan and KYTHERA filed ...
Breaking Medicine Technology:CTI BioPharma to Report Second Quarter 2015 Financial Results on August 6, 2015 2Regeneron and Sanofi Launch Major New Immuno-Oncology Collaboration 2Regeneron and Sanofi Launch Major New Immuno-Oncology Collaboration 3Regeneron and Sanofi Launch Major New Immuno-Oncology Collaboration 4Regeneron and Sanofi Launch Major New Immuno-Oncology Collaboration 5Regeneron and Sanofi Launch Major New Immuno-Oncology Collaboration 6Regeneron and Sanofi Launch Major New Immuno-Oncology Collaboration 7Regeneron and Sanofi Launch Major New Immuno-Oncology Collaboration 8Allergan and KYTHERA Announce Early Termination of Hart-Scott-Rodino Waiting Period for Allergan's Pending Acquisition of KYTHERA 2Allergan and KYTHERA Announce Early Termination of Hart-Scott-Rodino Waiting Period for Allergan's Pending Acquisition of KYTHERA 3Allergan and KYTHERA Announce Early Termination of Hart-Scott-Rodino Waiting Period for Allergan's Pending Acquisition of KYTHERA 4Allergan and KYTHERA Announce Early Termination of Hart-Scott-Rodino Waiting Period for Allergan's Pending Acquisition of KYTHERA 5Allergan and KYTHERA Announce Early Termination of Hart-Scott-Rodino Waiting Period for Allergan's Pending Acquisition of KYTHERA 6Allergan and KYTHERA Announce Early Termination of Hart-Scott-Rodino Waiting Period for Allergan's Pending Acquisition of KYTHERA 7Allergan and KYTHERA Announce Early Termination of Hart-Scott-Rodino Waiting Period for Allergan's Pending Acquisition of KYTHERA 8Allergan and KYTHERA Announce Early Termination of Hart-Scott-Rodino Waiting Period for Allergan's Pending Acquisition of KYTHERA 9
Keeler Professional Combi Retinoscope with new slimline handle and lithium or dry cell option....
300XL System, English (U.K. cord), 100-240 VAC....
Micro-mini fiber optic light....
Xenon technology achieves a higher efficiency than halogen light sources. Consequently they provide more light....
Medicine Products: